Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF

PhysicalIndex replication
AccumulatingDistribution policy
0.30 %TER
£11.89M Fund size
99Number of positions
— TD
47.70 %Top 10 share
USDCurrency
5SRI

Current price

£32.61
19 Nov 2026
1D
1W
1M
3M
6M
1Y
3Y
Max

Description

The fund is passively managed. The aim is for your investment to track the performance before fees and expenses of the MSCI ACWI IMI Genomic Innovation Select ESG Screened 100 Index (index). The index is based on the MSCI ACWI IMI Index (Parent Index) and is designed to reflect the performance of the shares of large, medium, and small-capitalisation companies globally that derive, or are expected to derive, significant revenues from technological innovation in the genomic healthcare sector. In order to be eligible for inclusion in the index, companies must be eligible for inclusion in the Parent Index and pass both thematic selection criteria and ESG screening criteria. The thematic selection criteria calculates a relevance score for potential constituents by assessing companies’ exposure to business activities associated with the theme. Securities must meet a certain relevance score threshold to be eligible for inclusion. The ESG screening criteria excludes companies from the Parent Index, which: (i) are unrated by MSCI ESG Research; (ii) are assigned an MSCI ESG Rating of CCC; (iii) have any involvement in controversial weapons; (iv) are classified by MSCI in their Business Involvement Screening Research as breaching certain revenue thresholds in controversial activities, including, but not limited to, tobacco, conventional weapons, nuclear weapons, civilian firearms, thermal coal and oil sands extraction; and/or (v) fail to comply with the United Nations Global Compact principles. The remaining securities are then ranked by their market capitalisation and the top 100 are selected for inclusion. Securities are finally weighted by a product of their freefloat adjusted market capitalisation and their relevance score. The index includes an issuer capping component, limiting the weight of each issuer to 4.5% at each quarterly rebalance. The index is administered by MSCI Limited. The index is calculated on a total return net basis, which means that all dividends and distributions by the companies are reinvested in the shares after tax. The index is reviewed semi-annually and rebalanced at least quarterly. The index is calculated in USD on a daily basis. To achieve the aim, the fund will attempt to replicate the index, before fees and expenses, by buying all or a substantial number of the securities in the index. The fund may employ techniques and instruments in order to manage risk, reduce costs and improve results. These techniques and instruments may include the use of financial contracts (derivatives). The fund may also engage in secured lending of its investments to certain eligible third parties subject to certain ESG criteria to generate additional income to offset the costs of the fund. Certain information (including the latest share prices of the fund, indicative net asset values, full disclosure on the composition of the fund's portfolio and information on the index constituents) are available on your local DWS website or at www.Xtrackers.com. Transaction costs and taxes, unexpected fund costs and market conditions such as volatility or liquidity issues may affect the ability of the fund to track the index. The anticipated level of tracking error in normal market conditions is 1 per cent. The currency of the fund is USD. Returns and gains are not distributed but are reinvested in the fund. You may request the redemption of shares generally on a daily basis.

Return

Here you can see the performance (incl. distributions) of the Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF.

Period Perfor­mance
1 Week-4.37 %
1 Month+0.15 %
3 Months+9.07 %
6 Months+37.09 %
1 Year+23.94 %
3 Years+51.20 %(14.78 % p.a.)
5 Years—
10 Years—
Since inception +17.22 %(3.72 % p.a.)
Year Perfor­mance
YTD+25.37 %
2025+5.17 %
2024+4.29 %
2023-6.98 %
2022-12.46 %
2021—
As of: 18 Nov 2026. Performance displayed in GBP

Master data

Key master data for the Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF

Total expense ratio (TER) 0.30 %
Index replication Physical
Replication method Full
Distribution policy Accumulating
Fund size £11.89M
Fund launch 12 Jul 2022
Fund currency USD
Currency hedging No 
Fund domicileIrland
Risk indicator (SRI)
5 · medium-high risk class

Risk metrics

Key risk and analysis metrics for the Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF

Volatility
21.58 % 1 Year
18.88 % 3 Years
— 5 Years
max. Drawdown
-10.14 % 1 Year
-17.30 % 3 Years
— 5 Years
Sharpe Ratio
1.31 1 Year
0.91 3 Years
— 5 Years
XLM
67.14

Information about the MSCI World Biotechnology 20/35 NR USD Index

Index name MSCI World Biotechnology 20/35 NR USD (1)
Included securities 117
Stock positions 99
Bond positions 0
Cash and other positions 18

More ETFs tracking the MSCI World Biotechnology 20/35 NR USD Index

Here you can find alternative index funds for the MSCI World Biotechnology 20/35 NR USD.

Fund nameWKNTER
No results

Frequently asked questions

Here you will find all answers to your questions about the Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF

Master data is provided by Morningstar (stocks, ETFs, funds), CoinGecko (cryptocurrencies) and Isarvest GmbH. Price data is at least 15-minute delayed exchange prices (stocks, ETFs, funds) or NAV prices (ETFs, funds). Real-time prices – where available – are provided by the providers and Lang & Schwarz (stocks, ETFs, funds) and CoinGecko (cryptocurrencies).

Isarvest GmbH assumes no liability for the information presented and cannot guarantee that the data is complete and accurate.

Affiliate notice *
Links marked with an asterisk (*) are advertising or affiliate links. If you purchase or sign up through this link, we receive compensation from the provider. This comes at no additional cost or disadvantage to you. We use this revenue to fund our free services. Thank you for your support.